Lilly’s Emgality fails to win CHMP support for cluster headaches

EMA’s CHMP rebuffed Lilly’s bid to treat cluster headaches with Emgality in its February roundup, which included a positive opinion on Shionogi’s antibiotic.

The agency issued a negative opinion to Eli Lilly and Co. (NYSE:LLY) for migraine drug Emgality galcanezumab, an anti-CGRP mAb, to prevent episodic cluster headaches. ...